Collegium Pharmaceutical, Inc. is a biotechnology company founded in 2002 with a mission to improve the lives of individuals facing severe medical conditions. The company boasts a diversified portfolio of innovative medications. The United States-based company recently secured a significant $203.20M post-IPO debt investment on 07 February 2023.
Collegium Pharmaceutical emphasizes its commitment to enhancing the well-being of individuals and strengthening communities, evident in their slogan, "Healthier people. Stronger communities." The recent substantial investment further underscores the company's potential to carve a prominent position in the pharmaceutical landscape.